TRIM58 Interacts with ZEB1 to Suppress NSCLC Tumor Malignancy by Promoting ZEB1 Protein Degradation via UPP

Figure 6

Inhibition effects of TRIM58-ZEB1 interaction on NSCLC tumor behavior were investigated. (a) Western blot and qRT-PCR were performed to investigate the impact of ZEB1 overexpression vector on ZEB1 expression. (b) Western blot and qRT-PCR experiment were performed to detect cancer stem-like cell markers including ALDH1 and CD44. Each experimental group was, respectively, treated with ZEB1 overexpression with or without TRIM58 overexpression vector. (c–e) Tumor cell line chemoresistance experiments were performed to detect NSCLC tumor survivability after treatment with different concentrations of docetaxel, doxorubicin, or gefitinib. Experimental cell group was, respectively, transfected with TRIM58 overexpression vector and/or ZEB1 overexpression vector. (f, g) Transwell experiment was performed to evaluate the effects of ZEB1 and/or TRIM58 overexpression vector transfection on NSCLC tumor cell invasion/migration. Percentage of migrated cells was calculated and analyzed. (h) EMT marker mRNA expression was measured with qRT-PCR after transfecting ZEB1 and/or TRIM58 overexpression vectors.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)